156 related articles for article (PubMed ID: 37711172)
1. CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome.
Park S; Lee S; Kim D; Kim H; Kwon YG
Front Pharmacol; 2023; 14():1242970. PubMed ID: 37711172
[No Abstract] [Full Text] [Related]
2. Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma.
Guan H; Singh NP; Singh UP; Nagarkatti PS; Nagarkatti M
PLoS One; 2012; 7(4):e35650. PubMed ID: 22532866
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury.
Kim Y; Bae CR; Kim D; Kim H; Lee S; Zhang H; Noh M; Kim YM; Mochizuki N; Kwon YG
J Inflamm (Lond); 2023 Apr; 20(1):13. PubMed ID: 37024954
[TBL] [Abstract][Full Text] [Related]
4. CU06-1004 alleviates vascular hyperpermeability in a murine model of hereditary angioedema by protecting the endothelium.
Lee S; Kim Y; Kim YS; Zhang H; Noh M; Kwon YG
Allergy; 2023 May; 78(5):1333-1346. PubMed ID: 36789476
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases.
Noh M; Kim Y; Zhang H; Kim H; Bae CR; Lee S; Kwon YG
Eur J Pharmacol; 2023 Jan; 939():175427. PubMed ID: 36509133
[TBL] [Abstract][Full Text] [Related]
6. Long-term administration of CU06-1004 ameliorates cerebrovascular aging and BBB injury in aging mouse model.
Kim H; Noh M; Zhang H; Kim Y; Park S; Park J; Kwon YG
Fluids Barriers CNS; 2023 Feb; 20(1):9. PubMed ID: 36726154
[TBL] [Abstract][Full Text] [Related]
7. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
8. CU06-1004 Alleviates Experimental Colitis by Modulating Colonic Vessel Dysfunction.
Kim YS; Zhang H; Lee S; Park S; Noh M; Kim YM; Kwon YG
Front Pharmacol; 2020; 11():571266. PubMed ID: 33041812
[TBL] [Abstract][Full Text] [Related]
9. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
Bae CR; Zhang H; Kwon YG
PLoS One; 2020; 15(12):e0243497. PubMed ID: 33275637
[TBL] [Abstract][Full Text] [Related]
10. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Shablak A; Gilham DE; Hawkins RE; Elkord E
Expert Opin Pharmacother; 2014 Aug; 15(11):1489-99. PubMed ID: 24890457
[TBL] [Abstract][Full Text] [Related]
11. CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury.
Zhang H; Kim H; Park BW; Noh M; Kim Y; Park J; Park JH; Kim JJ; Sim WS; Ban K; Park HJ; Kwon YG
Exp Mol Med; 2022 Jan; 54(1):23-34. PubMed ID: 34997212
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
[TBL] [Abstract][Full Text] [Related]
13. CU06-1004 modulates the adenosine monophosphate (AMP)-associated protein kinase (AMPK) signaling pathway and inhibits lipogenesis in 3T3-L1 adipocytes and high-fat diet-induced obese mice.
Bae CR; Kwon YG
Life Sci; 2022 May; 296():120440. PubMed ID: 35240161
[TBL] [Abstract][Full Text] [Related]
14. High-dose interleukin-2 therapy related adverse events and implications on imaging.
Shah NR; Declouette B; Ansari-Gilani K; Alhomoud MS; Hoimes C; Ramaiya NH; Güler E
Diagn Interv Radiol; 2021 Sep; 27(5):684-689. PubMed ID: 34559052
[TBL] [Abstract][Full Text] [Related]
15. Complete response to high-dose IL-2 and enhanced IFNγ+Th17 : TREG ratio in a melanoma patient.
Diller ML; Kudchadkar RR; Delman KA; Lawson DH; Ford ML
Melanoma Res; 2016 Oct; 26(5):535-9. PubMed ID: 27467756
[TBL] [Abstract][Full Text] [Related]
16. Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy.
Gores KM; Delsing AS; Kraus SJ; Powers L; Vaena DA; Milhem MM; Monick M; Doerschug KC
Shock; 2014 Aug; 42(2):115-20. PubMed ID: 24727870
[TBL] [Abstract][Full Text] [Related]
17. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.
Hanzly M; Aboumohamed A; Yarlagadda N; Creighton T; Digiorgio L; Fredrick A; Rao G; Mehedint D; George S; Attwood K; Kauffman E; Narashima D; Khushalani NI; Pili R; Schwaab T
Urology; 2014 May; 83(5):1129-34. PubMed ID: 24767525
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2.
Chemaly RF; Sharma PS; Youssef S; Gerber D; Hwu P; Hanmod SS; Jiang Y; Hachem RY; Raad II
Int J Infect Dis; 2010 Jul; 14(7):e548-52. PubMed ID: 20005762
[TBL] [Abstract][Full Text] [Related]
19. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma.
Guan H; Nagarkatti PS; Nagarkatti M
J Immunol; 2007 Sep; 179(6):3715-23. PubMed ID: 17785808
[TBL] [Abstract][Full Text] [Related]
20. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
Gill DM; Stenehjem DD; Parikh K; Merriman J; Sendilnathan A; Agarwal AM; Hahn AW; Gupta S; Tantravahi SK; Samlowski WE; Agarwal N
Ecancermedicalscience; 2016; 10():676. PubMed ID: 27729941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
